Overview

Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®

Status:
COMPLETED
Trial end date:
2025-07-22
Target enrollment:
Participant gender:
Summary
A Randomized, Double-blind, Controlled, Parallel-group, Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®
Phase:
PHASE1
Details
Lead Sponsor:
Xentria, Inc.